MicroPort Scientific Reports Strong Growth in 2024

MicroPort Scientific (HK:0853) has released an update.

MicroPort Scientific’s subsidiary, Shanghai MicroPort Endovascular MedTech, reported a significant financial performance for the first nine months of 2024, with a 9.13% increase in revenue and a 40.82% rise in profit compared to the same period last year. The net profit attributable to equity owners surged by 42.46%, indicating strong growth potential for investors. Despite the impressive results, investors are advised to consider these figures cautiously as they offer a limited view of the company’s overall operations.

For further insights into HK:0853 stock, check out TipRanks’ Stock Analysis page.